106 related articles for article (PubMed ID: 22488585)
1. Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.
Capello D; Gloghini A; Baldanzi G; Martini M; Deambrogi C; Lucioni M; Piranda D; Famà R; Graziani A; Spina M; Tirelli U; Paulli M; Larocca LM; Gaidano G; Carbone A; Sinigaglia F
Hematol Oncol; 2013 Mar; 31(1):22-8. PubMed ID: 22488585
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders.
Capello D; Deambrogi C; Rossi D; Lischetti T; Piranda D; Cerri M; Spina V; Rasi S; Gaidano G; Lunghi M
Br J Haematol; 2008 May; 141(4):504-11. PubMed ID: 18318760
[TBL] [Abstract][Full Text] [Related]
3. The clinical impact of DNA methylation frequencies of JAK2 negative regulators in patients with essential thrombocythemia.
Födermayr M; Zach O; Huber M; Machherndl-Spandl S; Wölfl S; Bösmüller HC; Hasenschwandtner S; Burgstaller S; Krieger O; Lutz D; Weltermann A; Hauser H
Leuk Res; 2012 May; 36(5):588-90. PubMed ID: 22325365
[TBL] [Abstract][Full Text] [Related]
4. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells.
Baus D; Pfitzner E
Int J Cancer; 2006 Mar; 118(6):1404-13. PubMed ID: 16206268
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells.
de Totero D; Capaia M; Fabbi M; Croce M; Meazza R; Cutrona G; Zupo S; Loiacono F; Truini M; Ferrarini M; Ferrini S
Exp Hematol; 2010 May; 38(5):373-83. PubMed ID: 20193734
[TBL] [Abstract][Full Text] [Related]
6. Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation.
Cooper JC; Shi M; Chueh FY; Venkitachalam S; Yu CL
Int J Oncol; 2010 May; 36(5):1201-8. PubMed ID: 20372794
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling.
Lejeune D; Demoulin JB; Renauld JC
Biochem J; 2001 Jan; 353(Pt 1):109-116. PubMed ID: 11115404
[TBL] [Abstract][Full Text] [Related]
8. Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis.
Ortiz-Muñoz G; Martin-Ventura JL; Hernandez-Vargas P; Mallavia B; Lopez-Parra V; Lopez-Franco O; Muñoz-Garcia B; Fernandez-Vizarra P; Ortega L; Egido J; Gomez-Guerrero C
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):525-31. PubMed ID: 19164812
[TBL] [Abstract][Full Text] [Related]
9. Abundant hypermethylation of SOCS-1 in clinically silent pituitary adenomas.
Buslei R; Kreutzer J; Hofmann B; Schmidt V; Siebzehnrübl F; Hahnen E; Eyupoglu IY; Fahlbusch R; Blümcke I
Acta Neuropathol; 2006 Mar; 111(3):264-71. PubMed ID: 16421738
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.
Johan MF; Bowen DT; Frew ME; Goodeve AC; Reilly JT
Br J Haematol; 2005 Apr; 129(1):60-5. PubMed ID: 15801956
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.
Jost E; do O N; Dahl E; Maintz CE; Jousten P; Habets L; Wilop S; Herman JG; Osieka R; Galm O
Leukemia; 2007 Mar; 21(3):505-10. PubMed ID: 17230231
[TBL] [Abstract][Full Text] [Related]
12. Calpastatin counteracts pathological angiogenesis by inhibiting suppressor of cytokine signaling 3 degradation in vascular endothelial cells.
Miyazaki T; Taketomi Y; Saito Y; Hosono T; Lei XF; Kim-Kaneyama JR; Arata S; Takahashi H; Murakami M; Miyazaki A
Circ Res; 2015 Mar; 116(7):1170-81. PubMed ID: 25648699
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
Calvisi DF; Ladu S; Gorden A; Farina M; Conner EA; Lee JS; Factor VM; Thorgeirsson SS
Gastroenterology; 2006 Apr; 130(4):1117-28. PubMed ID: 16618406
[TBL] [Abstract][Full Text] [Related]
14. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130.
Nicholson SE; De Souza D; Fabri LJ; Corbin J; Willson TA; Zhang JG; Silva A; Asimakis M; Farley A; Nash AD; Metcalf D; Hilton DJ; Nicola NA; Baca M
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6493-8. PubMed ID: 10829066
[TBL] [Abstract][Full Text] [Related]
15. The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling.
Fischer P; Lehmann U; Sobota RM; Schmitz J; Niemand C; Linnemann S; Haan S; Behrmann I; Yoshimura A; Johnston JA; Müller-Newen G; Heinrich PC; Schaper F
Biochem J; 2004 Mar; 378(Pt 2):449-60. PubMed ID: 14611646
[TBL] [Abstract][Full Text] [Related]
16. Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling.
van de Geijn GJ; Gits J; Touw IP
J Leukoc Biol; 2004 Jul; 76(1):237-44. PubMed ID: 15107455
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3.
Bergamin E; Wu J; Hubbard SR
Structure; 2006 Aug; 14(8):1285-92. PubMed ID: 16905102
[TBL] [Abstract][Full Text] [Related]
18. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals.
Evans MK; Yu CR; Lohani A; Mahdi RM; Liu X; Trzeciak AR; Egwuagu CE
Oncogene; 2007 Mar; 26(13):1941-8. PubMed ID: 17001312
[TBL] [Abstract][Full Text] [Related]
19. A family of cytokine-inducible inhibitors of signalling.
Starr R; Willson TA; Viney EM; Murray LJ; Rayner JR; Jenkins BJ; Gonda TJ; Alexander WS; Metcalf D; Nicola NA; Hilton DJ
Nature; 1997 Jun; 387(6636):917-21. PubMed ID: 9202125
[TBL] [Abstract][Full Text] [Related]
20. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities.
Mottok A; Renné C; Seifert M; Oppermann E; Bechstein W; Hansmann ML; Küppers R; Bräuninger A
Blood; 2009 Nov; 114(20):4503-6. PubMed ID: 19734449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
